Siddharth Paramhans

Strengthening Oral Health Promotion through Strategic Collaboration ​ We are delighted to announce that HRIDAY - Promoting Sustainable Health and ESIC Dental College & Hospital, Rohini, Delhi have entered into a Memorandum of Understanding (MoU) to advance oral health among school children in Delhi.​ This partnership marks the beginning of a collaborative journey under the Indian Council of Medical Research (ICMR)-led ANANT MUSKAAN study, which focuses on developing and implementing a school-based toothbrushing and oral health education model in Delhi.​ Together, we aim to improve oral hygiene practices, reduce dental caries, and foster healthier futures for our children. ​ Visit our website to learn more: https://hriday.org.in/​ Ministry of Health and Family Welfare, Government of India Indian Council of Medical Research (ICMR) Indian Dental Association (H.O.) FDI World Dental Federation Monika Arora Dr Mansi Chopra #HRIDAY #OralHealth #ANANTMuskaan #ICMR #SchoolHealth #PublicHealth #Collaboration #ESICDentalCollege #Toothbrushing #ICMRStudy #HealthPromotion #DentalCare #ResearchPartnership​

62

3 Comments

🚫 Gujarat Kidney IPO Review 🏥📉 | High-Risk Healthcare Issue ✨ [May Avoid Completely] Gujarat Kidney & Allied Super Speciality Ltd. (GKASSL) operates a multi-specialty hospital chain limited to Central Gujarat. Despite reporting growth in revenues and profits, several structural and valuation concerns make this IPO unattractive for most investors. Here’s a clear, point-by-point review ⬇️ 🔹 1️⃣ Limited Geographic Presence 🗺️⚠️ GKASSL operates only in Central Gujarat, which: ✔️ Restricts scalability ✔️ Increases regional risk ✔️ Limits long-term expansion visibility 🔹 2️⃣ Asset-Light Model with Lease Dependence 🏗️📄 The company follows an asset-light strategy, relying on leased hospital properties and inorganic growth. 📌 This results in: ✔️ High fixed rental costs ✔️ Pressure on margins during downturns ✔️ Lower operating leverage 🔹 3️⃣ Financial Growth Needs Caution 📊🔍 While both top line and bottom line have grown, the sharp margin improvement from FY24 onwards raises concerns: ✔️ Sustainability is uncertain ✔️ Margins may normalize in future ✔️ Competitive pressure could dent profitability 🔹 4️⃣ Highly Competitive & Fragmented Segment 🏥⚔️ Healthcare services at the regional level face: ✔️ Intense competition ✔️ Pricing pressure ✔️ Talent and cost challenges This makes long-term differentiation difficult. 🔹 5️⃣ Valuation – Greedily Priced 💵🚨 Based on recent financials, the IPO appears over-valued, offering: ✔️ Poor risk-reward ratio ✔️ Limited margin of safety ✔️ High downside risk 📌 Final Investment View 📝 ❌ Best avoided by retail investors ⚠️ Only well-informed / cash-surplus / high-risk investors may consider small exposure for medium term ✔️ Others are advised to skip this IPO ⭐ Like ❤️ Share 🔁 & Follow 👉 @stocks.insighthub For honest IPO reviews, risk analysis, healthcare sector insights, and exclusive newsletters, follow us on: 🔗 LinkedIn | Instagram | Threads | Telegram | Facebook | Snapchat | Twitter (X) | Quora | Pinterest | Blogspot | Linktree | WhatsApp | YouTube ⚠️ Disclaimer: This content is for educational purposes only and not investment advice. Please consult your financial advisor before investing. — @stocks.insighthub #GujaratKidneyIPO #IPOReview #AvoidIPO #HealthcareIPO #HighRiskInvestment #OvervaluedIPO #InvestorAlert #StocksInsightHub #IndianIPOs #MarketAnalysis #EquityInvestment #FinancialEducation #SmartInvesting #InvestorAwareness

4

Saurabh Gupta, Regional Chief Operating Officer, KIMS Hospitals, Thane, writes how MedTech and IVD are shaping India’s healthcare future in the October edition of 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘉𝘶𝘺𝘦𝘳. For complete perspective: https://lnkd.in/gGrj99fX #healthcare #MedTech #IVD #future #diagnostics #innovation #technology #cardiovascular #medical #devices #imaging #implants #challenge 

273

1 Comment

🌍 𝗜𝗩 𝗜𝗿𝗼𝗻 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 & 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 𝗣𝗼𝘀𝘁 𝟮 ( #𝗜𝗗𝗔)     The 𝗴𝗹𝗼𝗯𝗮𝗹 𝗶𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 (𝗜𝗩) 𝗶𝗿𝗼𝗻 𝗱𝗿𝘂𝗴𝘀 𝗺𝗮𝗿𝗸𝗲𝘁 reached 𝗨𝗦𝗗 𝟯.𝟯 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝟮𝟬𝟮𝟰 and is projected to grow to 𝗨𝗦𝗗 𝟱.𝟲 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟬 with a CAGR of ~9%. 🌎 Regional Dynamics • 𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮: ~50% market share (CKD & oncology-related anemia) • 𝗘𝘂𝗿𝗼𝗽𝗲: Strong adoption in IBD, gynecology, perioperative care • 𝗖𝗵𝗶𝗻𝗮 & #India:  High growth driven by anemia prevalence • #Saudi𝗔𝗿𝗮𝗯𝗶𝗮 & #UAE:  Emerging 𝗨𝗦𝗗 𝟬.𝟭–𝟬.𝟭𝟱𝗕 𝗺𝗮𝗿𝗸𝗲𝘁, with focus on oncology and CKD anemia treatments    💰 Market Leadership     𝗙𝗲𝗿𝗿𝗶𝗰 𝗖𝗮𝗿𝗯𝗼𝘅𝘆𝗺𝗮𝗹𝘁𝗼𝘀𝗲 (#𝗜𝗻𝗷𝗲𝗰𝘁𝗮𝗳𝗲𝗿 ® / #Ferinject  ®) dominates with ~50% global revenue share (~USD 1.8B in 2024). Although priced higher per mg, 𝗙𝗖𝗠 𝗶𝘀 𝗺𝗼𝗿𝗲 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗼𝘃𝗲𝗿𝗮𝗹𝗹: with 🧬 Clinical Outcomes : • #Hemoglobin  𝗿𝗶𝘀𝗲: 1–2 weeks • 𝗙𝘂𝗹𝗹 𝗮𝗻𝗲𝗺𝗶𝗮 𝗰𝗼𝗿𝗿𝗲𝗰𝘁𝗶𝗼𝗻: 4–8 weeks • 𝗙𝗲𝗿𝗿𝗶𝘁𝗶𝗻 𝗽𝗲𝗮𝗸𝘀: 2–4 weeks    ⚠️ 𝗧𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲: In iron deficiency anemia (#IDA), traditional IV iron corrects anemia only over 4–8 weeks. That’s valuable time lost — particularly during 𝗽𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 or in patients with high metabolic demands. ⚡ Biological Hemoglobin Oxygen Carrier (BHOC)  advantage   Here is where #𝗕𝗛𝗢𝗖 can 𝗯𝗿𝗶𝗱𝗴𝗲 𝘁𝗵𝗲 𝗴𝗮𝗽 𝗼𝗿 𝗲𝘃𝗲𝗻 𝗲𝗹𝗶𝗺𝗶𝗻𝗮𝘁𝗲 𝘁𝗵𝗲 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗶𝗿𝗼𝗻 𝗶𝗻𝗳𝘂𝘀𝗶𝗼𝗻 𝗱𝗿𝘂𝗴𝘀: • 𝗜𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝗮𝗻𝗲𝗺𝗶𝗮 𝗰𝗼𝗿𝗿𝗲𝗰𝘁𝗶𝗼𝗻 during infusion — time saved is critical . • 𝗗𝘂𝗮𝗹 𝗲𝗳𝗳𝗲𝗰𝘁: Many clinical trials show 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗲𝗿𝘆𝘁𝗵𝗿𝗼𝗽𝗼𝗶𝗲𝘀𝗶𝘀 𝘄𝗶𝘁𝗵𝗶𝗻 𝟳–𝟭𝟰 𝗱𝗮𝘆𝘀 • Acts as a 𝗻𝗮𝘁𝘂𝗿𝗮𝗹, 𝗵𝗶𝗴𝗵𝗹𝘆 𝗯𝗶𝗼𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗶𝗿𝗼𝗻 𝘀𝗼𝘂𝗿𝗰𝗲 integrated directly into the body hemoglobin pathway system    ✅ Same ultimate anemia correction as FCM, but 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗿𝗲 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲. ✅ BHOC can also be used 𝗰𝗼𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝗿𝗶𝗹𝘆 in severe cases, either before or alongside other iron therapies. ✅ 𝗕𝗛𝗢𝗖 𝗱𝗼𝗲𝘀𝗻’𝘁 𝗷𝘂𝘀𝘁 𝗯𝘂𝘆 𝗧𝗜𝗠𝗘 — 𝗶𝘁 𝗰𝗿𝗲𝗮𝘁𝗲𝘀 𝗶𝘁. 💬 Drop your thoughts, let discuss ! 𝘞𝘦 𝘯𝘦𝘦𝘥 𝘮𝘰𝘳𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘥𝘢𝘵𝘢 𝘧𝘰𝘤𝘶𝘴𝘦𝘥 𝘰𝘯 𝘵𝘩𝘢𝘵 𝘦𝘯𝘥𝘱𝘰𝘪𝘯𝘵; 𝘩𝘰𝘸𝘦𝘷𝘦𝘳, 𝘣𝘢𝘴𝘦𝘥 𝘰𝘯 𝘰𝘶𝘳 𝘤𝘶𝘳𝘳𝘦𝘯𝘵 𝘶𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦, 𝘸𝘦 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘩𝘪𝘴 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘴 𝘢 𝘯𝘦𝘸 𝘮𝘢𝘳𝘬𝘦𝘵 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺 𝘧𝘰𝘳 𝘉𝘏𝘖𝘊, 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘳𝘦𝘧𝘳𝘢𝘮𝘪𝘯𝘨 𝘖𝘹𝘺𝘨𝘦𝘯𝘢𝘵𝘪𝘰𝘯 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤𝘴. #IVIron #IDA  #IronDeficiency #IronDeficiencyAnemia #BHOC #Hematology #HealthcareInnovation #AnemiaTreatment #CKD #OncologyCare #MedicalBreakthrough #PatientCare #anemia #ishemia  #Bioavailability #GlobalHealthcare  #innovation #medicine #health #hospital

2

The Future of Interventional Cardiology Medtech in India: India is entering a defining decade for interventional cardiology. Today, the Indian interventional cardiology devices market is valued at around $800M and is projected to cross $1.8B by 2033, growing at nearly 8–9% CAGR. Even specific segments show strong expansion; as Coronary stent adoption alone exceeded $840M in 2023 and continues to grow with increasing PCI volumes. This growth reflects a powerful convergence of clinical need, technology innovation, and expanding healthcare access. With cardiovascular disease continuing to be the leading cause of mortality, demand for minimally invasive cardiac therapies is accelerating. PCI volumes are rising, cath labs are expanding beyond metro cities, and Indian cardiologists are increasingly managing complex coronary lesions. At the same time, the technology landscape is evolving rapidly. We are seeing greater adoption of precision imaging like IVUS and OCT, growth of complex PCI solutions such as atherectomy and intravascular lithotripsy, and increasing relevance of drug-coated balloons and specialty balloons. Structural heart interventions like TAVR are also expanding the boundaries of catheter-based therapy. However, the Indian market has its unique realities. Price regulation, cost sensitivity, infrastructure disparity, and procurement challenges continue to influence device adoption. Yet these same challenges are pushing the industry toward affordable innovation and indigenous manufacturing. A Quick SWOT Perspective: A)Strengths: Large patient population, skilled cardiologists, rising PCI volumes B)Weaknesses: Pricing pressure and uneven access to advanced technology C)Opportunities: Complex PCI tools, AI-enabled cath labs, Make-in-India medtech D)Threats: Market commoditization and regulatory constraints India is no longer just a high-volume PCI market. India is evolving from a volume-driven PCI market into a global center for cardiovascular innovation and clinical excellence. The next decade will belong to organizations and leaders who understand one critical truth: In India, innovation succeeds only when it becomes accessible. And those who can bridge that gap will shape the future of interventional cardiology. The real opportunity lies in balancing technology, clinical evidence, and affordability. #MedTech #InterventionalCardiology #HealthcareIndia #PCI #CardiologyInnovation #MedicalDevices

10

3 Comments

We at Asia Healthcare Holdings (AHH), are doubling down on our commitment to transform single-specialty healthcare in India. With a fresh ₹400 crore investment in the Asian Institute of Nephrology and Urology (AINU) over the next 4–5 years, we’re set to expand from 7 to 13 hospitals. From metros like Hyderabad and Chennai to Tier-2 cities such as Patna, Bhubaneswar, and Coimbatore, this expansion brings advanced Uro-Nephro care closer to where it’s needed most. 💡 What’s next? • State-of-the-art robotic surgery • Focus on Sub-specialties in Female and pediatric Urology • A scalable model ensuring high return on capital and better access in underserved markets AHH's total investment in AINU of ₹1,000 crore since FY24, makes it one of the largest investments in India’s single-specialty in the Urology-Nephrology space Asia Healthcare Holdings is on a mission to expand AINU’s footprint and bring advanced care closer to home. Big moves, bigger impact. Here’s to bridging healthcare gaps, one city at a time. 📰 Read the full story by Rica Bhattacharyya in The Economic Times: https://lnkd.in/grGhDdMp #HealthcareInvestment #UroNephrology #HospitalExpansion #Tier2Healthcare #RoboticSurgery #AsiaHealthcareHoldings

80

🏥💰 Running a Hospital = Balancing Care + Costs At Jaipur Eye & Dental Hospital, we believe that patient care is not only about clinical excellence but also about sustainable management. That’s why we recently conducted a staff training session on Hospital Income & Expense. 💡 Key points discussed: • Income allows us to invest in latest technology, medicines & staff salaries • Expenses cover essential areas like OT supplies, electricity, patient comfort & safety • Financial awareness among staff = smoother workflows, better resource allocation, and ultimately enhanced patient experience 👨‍⚕️ As Dr. Amit Gupta emphasized: “A hospital runs not just on compassion, but also on proper management and teamwork.” This culture of transparency & education ensures that every member of our team understands their role in building a sustainable, patient-first hospital ecosystem. 📌 We see healthcare as both a science and a responsibility — and strong financial management is the backbone that supports both. #HospitalManagement #HealthcareLeadership #SustainableHealthcare #PatientCareFirst #TeamJEDH #EyeCareIndia #DentalCareIndia

34

Time for India’s Traditional Optical Businesses to Think Long-Term and Go Corporate 👓 India’s optical retail chains — regional and national alike — along with lens manufacturers and frame importers have built the foundation of this industry through decades of trust, service, and personal relationships. But the next decade belongs to those who institutionalize their legacy. It’s time to corporatize, professionalize, and prepare for listing. Doing so will not only unlock massive enterprise value but also strengthen the entire optical ecosystem — creating opportunities for growth, employment, innovation, and investor confidence. When traditional optical businesses evolve into structured, listed organizations, it sends a clear message — that trust, tradition, and transparency can co-exist with technology, scalability, and modern governance. If this happens at scale, even new-age ventures like Lenskart and others will think twice before portraying traditional optical enterprises in a poor light — because they will stand shoulder to shoulder as credible, organized, and respected corporate institutions. The future of the Indian optical industry depends not just on products — but on vision, governance, and long-term thinking.

5

AMI News: IFAM India sets new standards in medical aesthetics education IFAM India leads in ethical, evidence-based aesthetic medicine education, offering hands-on training and advanced programmes for medical professionals. Read here: https://lnkd.in/ddz3dzBJ

1

SURGEON WORKING AS MEDICAL SPECIALIST In many parts of India, it has become increasingly common for medical specialists particularly surgeons and super specialists to extend their outpatient practice beyond the scope of their trained expertise and offer consultations for a wide range of general medical conditions. This trend is observed in both urban and semi-urban healthcare settings and is often driven by patient expectations, workforce shortages, or institutional convenience. While specialists are qualified medical practitioners, the practice of routinely managing chronic medical conditions such as hypertension, diabetes, rheumatologic disorders, hepatology-related illnesses, and other complex internal medicine concerns falls outside the purview of their formal specialist training. Such practices may inadvertently compromise the quality of care patients receive and may blur established professional boundaries within the healthcare system. Given the potential implications for patient safety, ethical medical practice, and the appropriate utilization of specialist skills, this issue merits careful attention. Local health authorities, regulatory bodies, and institutional administrators should recognize this growing pattern and consider appropriate guidelines, monitoring mechanisms, and awareness initiatives to ensure that patients receive care from the most appropriately trained specialists. Regards, JAKSTAR PHARMA

2

Absolutely agree Akshat Gumbhir. Digital dentistry in India is no longer a trend — it’s a structural shift. The real transformation will come when education, industry, and clinical practice move together in a synchronized ecosystem. At Unicorn Denmart Ltd., we believe scalable digital adoption must begin at the student level — shaping future-ready clinicians before they enter practice. The next phase isn’t just about technology. It’s about building capability.

31

A power-packed conversation on Surgical Oncology with expert insights and real patient-centric perspectives. Featuring: Dr. Ashish – Surgical Oncology Specialist Harleen Gambhir – Head – Branding & PR Communication From complex cancers to advanced surgical treatments – understand what really matters for better outcomes and informed decisions. Stay tuned… Podcast releasing soon! #SurgicalOncology #HealthPodcast #CancerCare #OncologyExpert #MedicalTalks #HealthcareInsights #GeetanjaliHospital #CancerAwareness #PatientCare #MedicalEducation #PodcastSeries #ComingSoon

12

MEDICAL UPDATES AIIMS-Led Survey Reveals Private Sector Dominance in India’s Eye Care System - https://lnkd.in/dM8UDuYs Sankara Eye Hospital Expands Vision Care with New Super Speciality Facility in Guntur - https://lnkd.in/dpBD_nig Cells Use Mechanical Tension to Shape Organs, NCBS Study Finds - https://lnkd.in/d7ZarSTb PharmEasy Sounds Alarm on India’s Silent Health Emergency — Diabetes - https://lnkd.in/daHXmTeK KIMS Cuddles Thane Unveils Mrs. Mom Season 9 with the Theme “9 Months – Core Value”https://lnkd.in/dxNcEWy2 -------------- #EyeCare #EyeHealth #VisionCare #NCBS #OrganFormation #BloodSugar #Bioengineering #Diabetes #HealthEmergency #DiseaseManagement #MrsMomSeason9 #MaternityCare #Health #Healthcare #Drugs #Pharma #Pharmaceuticals #MedicalDevice #Drugsandpharma #HealthPractitioner #PharmaSector #Medtech #MedicalService #MedicalPractitioner

3

📢 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆- 𝗔 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗹𝗮𝗯 𝗰𝗵𝗮𝗶𝗻 𝘄𝗶𝘁𝗵 30+ 𝗰𝗲𝗻𝘁𝗿𝗲𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗠𝘂𝗺𝗯𝗮𝗶 𝗶𝘀 𝗲𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝗮 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝘀𝗮𝗹𝗲. 𝗞𝗲𝘆 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: • Integrated service portfolio covering pathology & radiology • Established footprint with strong brand recall in Western India • Proven scalability through a mix of company-owned and franchise models • 20% EBITDA margin • Improved working capital efficiency and operational discipline With the Indian diagnostics sector projected to grow at ~14% CAGR, this represents a compelling consolidation opportunity in healthcare services. 🔎 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀, 𝗣𝗘 𝗳𝘂𝗻𝗱𝘀, 𝗮𝗻𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 exploring opportunities in diagnostics are welcome to connect for further details. #Healthcare #Diagnostics #InvestmentOpportunity #PrivateEquity #MergersAndAcquisitions #India

12

5 Comments